Search jobs 01-Jun-2021 Heartseed and Novo Nordisk enter into global collaboration and licence agreement for stem cell-based therapy for heart failure
Bagsværd
, Denmark and Tokyo, Japan, 1 June 2021 – Heartseed Inc. and Novo Nordisk A/S today announced that they have entered into an exclusive worldwide collaboration and licence agreement for development, manufacturing and commercialisation of Heartseed’s lead asset HS-001.
HS-001 is an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC), which is currently under development by Heartseed for the treatment of heart failure.
Heartseed is planning to initiate a phase 1/2 clinical trial in Japan (LAPiS Study) in the second half of 2021 evaluating the safety and efficacy of HS-001 for the treatment of heart failure caused by ischemic heart disease. Japan’s Pharmaceutical and Medical Devices Agency has approved Heartseed
Haines School one of few in Alaska to open on time, all year
May 27, 2021
As the Haines School year came to a close last week, administrators and staff celebrated the district that was one of few that started on time and remained open for in-person classes throughout the year during the COVID-19 pandemic.
The Alaska Department of Education and Early Development (DEED) provided guidance to school districts, what it called the “Alaska Smart Start Plan,” but ultimately left it to each school district to approve how it would organize the school year.
DEED doesn’t keep track of how many schools remained open or started on time, but director of DEED’s Division of Innovation and Education Excellence Tammy Van Wyhe said the fact that Haines was able to do so was noteworthy.
Exscientia.
The agreement includes up to $50 million in upfront funding, up to $125 million in near to mid-term potential milestones, and additional clinical, regulatory and commercial payments that take the potential value of the deal beyond $1.2 billion. Exscientia will also receive royalties on net sales of any marketed drug products resulting from the collaboration.
The biotech industry is increasingly using AI to deploy targeted drug molecules to test the efficacy of drugs to tackle illnesses ranging from cancer to heart disease. Headquarters of Bristol-Myers Squibb Germany in Munich, Germany.
Andrew Hopkins, CEO of Exscientia, commented, “…this expanded collaboration …speaks to the strength and promise of Exscientia’s AI technologies and drug discovery expertise. We’re excited to work with such an experienced collaborator as Bristol Myers Squibb to develop the best possible medicines for patients.”